Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$185.68 USD

185.68
1,137,205

+0.90 (0.49%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Alibaba, Costco, Walgreens Boots, Biogen and PayPal

The Zacks Analyst Blog Highlights: Alibaba, Costco, Walgreens Boots, Biogen and PayPal

    Biogen (BIIB) Presents Positive Phase III Data on Spinraza

    Biogen Inc. (BIIB) presented positive data from the phase III ENDEAR study evaluating Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).

      Arpita Dutt headshot

      Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again

      Drug stocks were hit once again with President-elect Donald Trump's comments about the sector at his first news conference since his election in November.

        Biogen Licenses Amunix's XTEN Technology for Factor IX Drug

        Biogen Inc. (BIIB) exercised its option to enter into an exclusive, global license agreement with Amunix Operating Inc. to incorporate the latter's proprietary XTEN half-life extension technology in developing a recombinant Factor IX candidate.

          Ionis (IONS) Stock Up on Positive Type II Diabetes Drug Data

          Ionis (IONS) announced positive data from a phase II study on IONIS-GCGR for the treatment of patients with type II diabetes.

            AbbVie's Humira and Imbruvica Drive Performance in 2016

            AbbVie Inc.'s (ABBV) share price is up 5.9% so far this year.

              Arpita Dutt headshot

              Biotech Stock Roundup: FDA Nod for Biogen/Ionis Drug, Seattle Genetics Hit by Clinical Hold

              Biogen (BIIB) and Ionis got an early Christmas gift with the FDA approving their spinal muscular atrophy drug within three months of regulatory filing.

                Ionis/Biogen Spinraza Approved For Spinal Muscular Atrophy

                Ionis (IONS) and Biogen (BIIB) announced that FDA has approved Spinraza under Priority Review for the treatment of spinal muscular atrophy.

                  Arpita Dutt headshot

                  Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug

                  Biotech stocks like Conatus (CNAT) and Clovis reported positive developments this week with one company signing a deal and the other getting accelerated FDA approval for its cancer treatment.

                    Biogen (BIIB) Board Okays Hemophilia Business Spin-off

                    Biogen (BIIB) announced that its board of directors has approved the spin-off of its hemophilia business into a new company Bioverativ Inc.

                      Biogen Names Commercial Officer as New CEO, Shares Fall

                      Biogen Inc. (BIIB) has appointed its present chief commercial officer (CCO), Michel Vounatsos, as the new chief executive officer (CEO), effective Jan 6, 2017.

                        The Zacks Analyst Blog Highlights: Barclays, Netflix, NIKE, Biogen and China Petroleum & ChemicalThe Zacks Analyst Blog Highlights: Barclays, Netflix, NIKE, Biogen and China Petroleum & Chemical

                        The Zacks Analyst Blog Highlights: Barclays, Netflix, NIKE, Biogen and China Petroleum & Chemical

                          Arpita Dutt headshot

                          Biotech Stock Roundup: Ophthotech Slumps on Fovista Results, Achaogen Skyrockets on Data

                          Several companies presented data this week with companies like Achaogen (AKAO) soaring while others like Ophthotech plunged.

                            Mark Vickery headshot

                            Top Research Reports for Barclays, Netflix and Nike

                            Today's Research Daily features new research reports on 16 major stocks, including Barclays (BCS), Netflix (NFLX) and NIKE (NKE).

                              Biogen Presents Positive Early Data from Alzheimer's Study

                              Last week, Biogen Inc. (BIIB) presented positive data from a phase I study (PRIME) on its anti-amyloid treatments in development, aducanumab, at the Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego.

                                Lilly/AstraZeneca Expand Alzheimer Disease Collaboration

                                Eli Lilly and Company (LLY) and AstraZeneca plc (AZN) expanded their existing collaboration to develop the second treatment for Alzheimer's disease, MEDI1814

                                  Stock Market News for December 08, 2016

                                  The Trump induced rally continued to boost major benchmarks to finish at all-time record highs on Wednesday offsetting the decline in healthcare stocks.

                                    GW Pharmaceuticals (GWPH): What Awaits in Q4 Earnings?

                                    GW Pharmaceuticals (GWPH) is set to report fourth-quarter fiscal 2016 results on Dec 5. The company posted positive surprise of 57.80% in the last quarter.

                                      Arpita Dutt headshot

                                      Biotech Stock Roundup: Actelion Soars on Acquisition Talks, Another Clinical Hold for Juno

                                      With Johnson & Johnson eyeing Actelion (ALIOF), will mergers and acquisitions pick pace in the biotech sector?

                                        The Zacks Analyst Blog Highlights: Biogen, Honda, Intel, CSX and General Growth Properties

                                        The Zacks Analyst Blog Highlights: Biogen, Honda, Intel, CSX and General Growth Properties

                                          Sheraz Mian headshot

                                          Top Research Reports for Intel, Honda & Biogen

                                          Today's Research Daily features new research reports on 16 major stocks, including Biogen (BIIB), Honda (HMC) and Intel (INTC).

                                            Company News for November 08, 2016

                                            Companies in the News are: BRK.B,LC,BID,BIIB,IONS

                                              Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals

                                              Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals

                                                Arpita Dutt headshot

                                                Fundamentals Remain Strong in the Pharma Sector

                                                We could see several M&A agreements being announced in the coming quarters, though companies are wary of bidding wars leading to over-priced deals.

                                                  Stock Market News for October 12, 2016

                                                  Disappointing start to the third quarter earnings season weighed on benchmarks on Tuesday